Macomber Lori 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) CFO Lori Macomber Receives 32,415-Share Award
What Happened
- Lori Macomber, EVP, Chief Financial Officer and Treasurer of Karyopharm Therapeutics, received an award of 32,415 restricted stock units (RSUs) on January 31, 2026. The reported acquisition price is $0.00 (award), so there was no purchase cost at grant. This is a compensation grant (not an open-market buy or sell).
Key Details
- Transaction date: 2026-01-31; Form 4 filed: 2026-02-03 (timely filing).
- Transaction type: A (Award/Grant) — 32,415 RSUs granted at $0.00.
- Shares owned following the transaction: not specified in the provided filing data.
- Footnote: RSUs convert one-for-one into common stock. Vesting: 50% on January 31, 2027 and 50% on January 31, 2028 (per the 2022 Equity Incentive Plan, as amended).
- No tax withholding, sale, or 10b5-1 plan is indicated in the reported transaction.
Context
- RSU grants are a common form of executive compensation and do not require an immediate cash outlay; they only become actual shares as they vest. Such awards are compensation-related and should not be interpreted on their own as a definitive signal of the insider’s near-term view of the stock.
Insider Transaction Report
Form 4
Macomber Lori
EVP, CFO & Treasurer
Transactions
- Award
Common Stock
[F1]2026-01-31+32,415→ 86,731 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.
Signature
/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber|2026-02-03